Research Centre for Obesity,
Diabetes and Cardiovascular Complications

With the approval of the Ministry of Science and Technology of the Central Government, the Partner State Key Laboratory of Pharmaceutical Biotechnology has been established at HKU in July, in strategic collaboration with the State Key Laboratory of Pharmaceutical Biotechnology at Nanjing University, bringing the number of State Key Laboratories at HKU to five.

Located at the Li Ka Shing Faculty of Medicine, the Partner State Key Laboratory of Pharmaceutical Biotechnology is run by the Department of Medicine and the Department of Pharmacology and Pharmacy, with a team of nearly 80 researchers.

The Laboratory aims to conduct basic, clinical and translational research on obesity, diabetes and its cardiovascular complications, and to facilitate scholarly and research exchanges with the Mainland and international scientists for the benefit of pharmaceutical industries and clinical practice in Hong Kong and Mainland China.

Being regarded as key components of China’s science and technology research system, the State Key Laboratories serve as the base for top-level basic research and applied basic research development, assembling and nurturing outstanding researchers, as well as scholarly exchanges for the country. There are over 260 State Key Laboratories throughout China.

Currently, HKU has five State Key Laboratories; the other four are Partner State Key Laboratory of Emerging Infectious Diseases, Partner State Key Laboratory of Brain and Cognitive Sciences, Partner State Key Laboratory on Synthetic Chemistry and Partner State Key Laboratory for Liver Research.■